Harmony Biosciences (HRMY) Stock Price, News & Analysis

Company Overview

Harmony Biosciences Holdings, Inc. is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. WAKIX was granted approval in August 2019 following pivotal Phase III clinical trials demonstrating its efficacy and tolerability profile. Harmony Biosciences has established a commercial infrastructure across the United States to support patient access, education, and ongoing research into expanded indications.

In addition to its marketed therapy, Harmony Biosciences maintains a clinical development program to evaluate pitolisant in other sleep disorders and cognitive conditions, leveraging its expertise in histaminergic modulation. The company collaborates with academic institutions, patient advocacy groups, and specialty pharmacies to facilitate real‐world data collection and to enhance support services for patients and healthcare providers. Harmony continues to explore strategic partnerships and licensing arrangements to extend its reach into international markets.

Harmony Biosciences is led by President and Chief Executive Officer Joseph P. Woody, whose leadership team brings together experience in specialty pharmaceuticals, regulatory affairs, and commercial operations. With a focus on patient‐centric innovation and long‐term value creation, Harmony Biosciences aims to address unmet needs in rare disease communities while expanding its pipeline and geographic footprint.

Key Stats

• Today's Range: $31.61 to $32.58
• 50-Day Range: $32.24 to $38.05
• 52-Week Range: $26.47 to $41.61
• Volume: 808,174 shs
• Average Volume: 663,219 shs
• Market Capitalization: $1.87 billion
• P/E Ratio: 10.48
• Dividend Yield: N/A
• Price Target: $51.00
• Consensus Rating: Buy

Harmony Biosciences Stock Analysis - MarketRank™

Harmony Biosciences scored higher than 92% of companies evaluated by MarketBeat, and ranked 92nd out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Harmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Harmony Biosciences has a consensus price target of $51.00, representing about 56.9% upside from its current price of $32.50.

Amount of Analyst Coverage

Harmony Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 27.98%

Earnings Growth

Earnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Harmony Biosciences is 10.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.44.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harmony Biosciences is 10.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.99.

Price to Earnings Growth Ratio

Harmony Biosciences has a PEG Ratio of 0.38. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Harmony Biosciences has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.70% of the float of Harmony Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Harmony Biosciences has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Harmony Biosciences has recently increased by 1.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harmony Biosciences does not currently pay a dividend.

Dividend Growth

Harmony Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.70% of the float of Harmony Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Harmony Biosciences has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Harmony Biosciences has recently increased by 1.41%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.50

News Sentiment

Harmony Biosciences has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Harmony Biosciences this week, compared to 7 articles on an average week.

Search Interest

15 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 114% compared to the previous 30 days.

MarketBeat Follows

4 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harmony Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HRMY Stock Analysis - Frequently Asked Questions

How have HRMY shares performed this year?

Harmony Biosciences' stock was trading at $34.41 on January 1st, 2025. Since then, HRMY stock has decreased by 5.6% and is now trading at $32.50.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings results on Tuesday, August, 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by $0.10. The firm's revenue was up 16.0% compared to the same quarter last year.
Read the conference call transcript.

When did Harmony Biosciences IPO?

Harmony Biosciences (HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Who are Harmony Biosciences' major shareholders?

Harmony Biosciences' top institutional shareholders include American Century Companies Inc. (2.61%), LSV Asset Management (2.59%), Marshall Wace LLP (2.10%) and Geode Capital Management LLC (1.83%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Sandip Kapadia, Jeffrey M Dayno and Jeffrey Dierks.
View institutional ownership trends.

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HRMY
• CIK: 1802665
• Web: www.harmonybiosciences.com
• Phone: 484-539-9800
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Harmony Biosciences: $51.00
• High Price Target: $70.00
• Low Price Target: $33.00
• Potential Upside/Downside: +57.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.10
• Trailing P/E Ratio: 10.45
• Forward P/E Ratio: 13.33
• P/E Growth: 0.38
• Net Income: $145.49 million
• Net Margins: 23.44%
• Pretax Margin: 29.14%
• Return on Equity: 26.34%
• Return on Assets: 17.71%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 3.84
• Quick Ratio: 3.80

Sales & Book Value

• Annual Sales: $714.73 million
• Price / Sales: 2.61
• Cash Flow: $2.95 per share
• Price / Cash Flow: 10.99
• Book Value: $11.56 per share
• Price / Book: 2.80

Miscellaneous

• Outstanding Shares: 57,530,000
• Free Float: 43,955,000
• Market Cap: $1.86 billion
• Optionable: Optionable
• Beta: 0.84